Answers are grounded in this paper and cite their sources.
• Chordoma is a challenging malignancy, and treatment options for recurrent and metastatic cases are limited. • A majority of chordomas exhibit negative thymidylate synthase (TS) expression, implying a potential response to pemetrexed. • Pemetrexed exerts its effects by inhibiting key enzymes such as thymidylate synthase (TS). • Chordomas are rare with limited literature addressing novel treatment strategies and a lack of clinical trial data. Chordomas are a rare slow growing tumor with a high recurrence rate that originate from residual embryonic notochord cells, primarily affecting the axial skeleton. Currently limited treatment options exist beyond surgery and radiation, and systemic chemotherapy has shown limited efficacy. The majority of chordomas exhibit negative thymidylate synthase (TS) expression, implying a potential responsiveness to the antifolate agent pemetrexed. We present a case report of a 78-year-old patient with recurrent, metastatic sacral chordoma who showed clinical and radiological improvement with pemetrexed treatment. The patient received 12 cycles of pemetrexed which resulted in a decrease in the size of liver and lung lesions. Moreover, the patient experienced resolution of debilitating symptoms, including right leg weakness, and unsteady gait. This case report highlights the use of pemetrexed as a therapeutic option for recurrent and metastatic chordoma. Further research is warranted to explore the optimal use of pemetrexed in chordoma management and identify predictive biomarkers for treatment response.
No takes yet. Share an insight, caveat, or question.
Celestino et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: